Qiagen NV
QGEN
44.79
-0.86
-1.88%
Qiagen NV
US · QGEN
#1551 by market cap
Listed 1970
44.79
-0.86
-1.88%
Live - 5344 symbols - heartbeat 128s ago
· 2026-10-08 08:13
Pre-market
44.34
-1.00%
After-hours
44.79
0.00%
Overnight
44.75
-0.09%
- Market cap
- 9.25B
- P/E (TTM)i
- 22.77
- P/Bi
- 2.75
- EPSi
- 1.94
- Div yieldi
- 0.78%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on QGEN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.72, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.65% YoY
Margins
- Gross margin
- 62.18%
- Operating margin
- 24.90%
- Net margin
- 20.33%
Key ratios & quality
- Enterprise valuei
- 9.83B
- PEG ratioi
- 173.42
- Altman Z-Scorei
- 3.72
PEG uses trailing P/E against the 3-year net income growth rate (0.13%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50B | 1.53B | 1.87B | 2.25B | 2.14B | 1.97B | 1.98B | 2.09B |
| Gross profit | 1.00B | 1.01B | 1.23B | 1.45B | 1.38B | 1.23B | 967.35M | 1.30B |
| Selling & admin expenses | 496.85M | 504.17M | 525.36M | 584.47M | 603.95M | 579.17M | 564.36M | 583.67M |
| Research & development | 161.85M | 157.45M | 149.07M | 189.96M | 189.86M | 198.51M | 193.49M | 187.52M |
| Operating profit | 303.23M | 313.67M | 537.47M | 657.85M | 576.23M | 445.25M | 199.90M | 520.31M |
| Pretax profit | 225.74M | -77.78M | 439.47M | 625.83M | 512.60M | 429.81M | 121.15M | 490.27M |
| Tax | 35.36M | -36.32M | 80.28M | 113.23M | 89.39M | 88.51M | 37.56M | 65.39M |
| Net profit | 190.38M | -41.46M | 359.19M | 512.60M | 423.21M | 341.30M | 83.59M | 424.88M |
| Basic EPS | 1 | 0 | 2 | 3 | 2 | 2 | 0 | 2 |
| Diluted EPS | 0.92 | -0.20 | 1.71 | 2.47 | 2.05 | 1.65 | 0.41 | 2.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 483.46M | 533.54M | 532.58M | 540.42M | 492.32M | 535.04M |
| Gross profit | 308.68M | 334.29M | 331.26M | 325.27M | 309.60M | 340.39M |
| Selling & admin expenses | 137.94M | 148.75M | 143.11M | 153.88M | 142.39M | 146.77M |
| Research & development | 43.78M | 47.75M | 48.75M | 47.24M | 48.26M | 50.43M |
| Operating profit | 125.16M | 135.97M | 137.29M | 121.88M | 116.63M | 140.85M |
| Pretax profit | 119.55M | 126.82M | 134.73M | 109.17M | 85.83M | 132.11M |
| Tax | 28.79M | 30.57M | 4.68M | 1.34M | 17.79M | 28.70M |
| Net profit | 90.76M | 96.25M | 130.04M | 107.83M | 68.04M | 103.40M |
| Basic EPS | 0 | 0 | 1 | 1 | 0 | 1 |
| Diluted EPS | 0.43 | 0.46 | 0.63 | 0.52 | 0.33 | 0.50 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.16B | 1.57B | 1.62B | 2.11B | 2.39B | 2.15B | 1.96B | 2.00B |
| Cash & ST investments | 1.39B | 753.23M | 715.23M | 1.07B | 1.42B | 1.06B | 1.15B | 1.10B |
| Inventory | 162.91M | 170.70M | 291.18M | 327.53M | 357.96M | 398.39M | 279.26M | 301.89M |
| Total assets | 5.75B | 5.24B | 5.87B | 6.15B | 6.29B | 6.12B | 5.69B | 6.28B |
| Total current liabilities | 972.19M | 951.35M | 572.18M | 1.52B | 974.52M | 1.08B | 1.04B | 512.14M |
| Short-term debt | 503.12M | 303.98M | 65.99M | 869.67M | 411.77M | 610.24M | 576.22M | 28.84M |
| Long-term debt | 1.67B | 1.42B | 1.88B | 1.09B | 1.47B | 921.82M | 839.67M | 1.65B |
| Total liabilities | 3,113,362,000.00 | 2,699,025,000.00 | 3,071,780,000.00 | 3,050,404,000.00 | 2,821,124,000.00 | 2,307,426,000.00 | 2,122,283,000.00 | 2,503,078,000.00 |
| Total equity | 2.63B | 2.54B | 2.80B | 3.10B | 3.47B | 3.81B | 3.57B | 3.78B |
| Retained earnings | 1.38B | 1.18B | 1.32B | 1.79B | 2.16B | 2.46B | 2.45B | 2.75B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.74B | 1.82B | 2.53B | 2.00B | 1.54B | 1.66B |
| Cash & ST investments | 963.45M | 953.82M | 1.69B | 1.10B | 646.29M | 793.50M |
| Inventory | 281.36M | 292.55M | 290.23M | 301.89M | 309.61M | 311.36M |
| Total assets | 5.55B | 5.82B | 6.55B | 6.28B | 5.78B | 5.89B |
| Total current liabilities | 516.94M | 1.13B | 973.41M | 512.14M | 479.11M | 581.45M |
| Short-term debt | 55.69M | 559.19M | 499.60M | 28.84M | -- | 16.52M |
| Long-term debt | 1.35B | 884.85M | 1.63B | 1.65B | 1.65B | 1.63B |
| Total liabilities | 2,137,492,000.00 | 2,318,268,000.00 | 2,904,082,000.00 | 2,503,078,000.00 | 2,450,359,000.00 | 2,531,462,000.00 |
| Total equity | 3.41B | 3.51B | 3.65B | 3.78B | 3.33B | 3.36B |
| Retained earnings | 2.50B | 2.52B | 2.65B | 2.75B | 2.80B | 2.81B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 359.50M | 330.84M | 457.81M | 639.00M | 715.26M | 459.46M | 673.55M | 654.33M |
| Depreciation & amortization | 206.44M | 231.46M | 205.01M | 214.93M | 208.40M | 205.34M | 203.27M | 193.75M |
| Free cash flow | 208.73M | 55.96M | 153.57M | 432.47M | 565.93M | 296.65M | 502.31M | 447.20M |
| Dividends paid | -- | -- | -- | -- | -- | 0 | 0 | -54.24M |
| Stock buybacks / issuance | -100.27M | -72.38M | -56.33M | -92.07M | 0 | -- | -- | -- |
| Ending cash balance | 1.16B | 629.39M | 597.98M | 880.52M | 730.67M | 668.08M | 663.56M | 839.01M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 139.74M | 161.44M | 165.02M | 188.13M | 100.63M | 200.69M |
| Depreciation & amortization | 43.91M | 49.48M | 50.97M | 49.39M | 51.21M | 50.56M |
| Free cash flow | 95.48M | 120.60M | 114.57M | 116.55M | 52.15M | 157.32M |
| Dividends paid | -- | -- | -- | 1.00K | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | -- | -- | -- |
| Ending cash balance | 638.76M | 733.82M | 1.36B | 839.01M | 646.29M | 768.50M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 7.36 | -1.60 | 13.47 | 17.39 | 12.90 | 9.38 | 2.27 | 11.57 |
| ROA %i | 3.53 | -0.75 | 6.44 | 8.50 | 6.81 | 5.50 | 1.42 | 7.10 |
| ROIC %i | 5.04 | -0.08 | 9.09 | 11.21 | 8.54 | 6.01 | 1.30 | 7.53 |
| 5-year avg ROE %i | 4.27 | 3.08 | 4.78 | 7.64 | 9.90 | 10.31 | 11.08 | 10.70 |
| EBIT margin %i | 19.51 | -0.24 | 27.31 | 30.21 | 26.66 | 24.59 | 8.34 | 25.05 |
| FCF / sales %i | 13.90 | 3.67 | 8.21 | 19.21 | 26.43 | 15.09 | 25.39 | 21.40 |
| Current ratioi | 2.22 | 1.65 | 2.84 | 1.39 | 2.46 | 1.99 | 1.88 | 3.90 |
| Quick ratioi | 1.87 | 1.31 | 2.10 | 1.01 | 1.90 | 1.46 | 1.55 | 3.16 |
| Debt / assetsi | 37.82 | 32.95 | 33.16 | 31.95 | 29.96 | 25.05 | 26.58 | 28.85 |
| LT debt / equityi | 63.42 | 56.02 | 67.20 | 35.33 | 42.46 | 24.21 | 26.25 | 47.21 |
| Interest coveragei | 4.35 | -0.05 | 7.16 | 12.49 | 9.78 | 9.05 | 3.76 | 15.74 |
| Revenue CAGR (3Y) %i | 5.45 | 4.49 | 9.68 | 14.45 | 11.95 | 1.66 | -4.22 | -0.81 |
| Net income CAGR (3Y) %i | 13.52 | -- | 107.17 | 39.12 | -- | -1.69 | -45.37 | 0.13 |
| FCF CAGR (3Y) %i | 1.43 | -39.09 | -1.84 | 27.48 | 116.25 | 24.54 | 5.12 | -7.55 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 2.67 | 10.81 | 11.29 | 11.57 | 11.93 | 11.93 |
| ROA %i | 1.65 | 6.55 | 6.32 | 7.10 | 7.10 | 6.99 |
| ROIC %i | 1.55 | 7.26 | 6.86 | 7.53 | 7.85 | 7.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.95 | 25.79 | 26.14 | 25.05 | 23.52 | 23.87 |
| FCF / sales %i | 25.12 | 24.31 | 22.82 | 21.40 | 19.24 | 20.98 |
| Current ratioi | 3.37 | 1.61 | 2.60 | 3.90 | 3.21 | 2.85 |
| Quick ratioi | 2.52 | 1.19 | 2.12 | 3.16 | 2.18 | 2.04 |
| Debt / assetsi | 25.40 | 24.80 | 32.46 | 28.85 | 28.48 | 27.91 |
| LT debt / equityi | 39.69 | 25.24 | 44.60 | 47.21 | 49.42 | 48.46 |
| Interest coveragei | 4.39 | 14.02 | 15.80 | 15.74 | 13.33 | 12.71 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Diagnostic solutions is the largest reported line at 38.11% of revenue, across 5 reported segments.
- No single line clears half of revenue; Sample technologies is next at 34.05%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Diagnostic solutions38.11%
Sample technologies34.05%
Polymerase Chain Reaction (PCR) / Nucleic acid amplification13.80%
Genomics / Next-Generation Sequencing (NGS)11.33%
Other2.71%
Quote time 2026-10-08 08:13:50 · For reference only, not investment advice and not tailored to your situation.